For the qualitative assessment of COVID-19(SARS-CoV-2) neutralizing antibody after the vaccination in human serum/plasma/whole blood. Sensitivity: 95.39% Specificity: >99.9% Accuracy: 98.47% CE Certificate available.
INVBIO Covid Antigen Ag saliva rapid test card Sensitivity: 97.1% Specificity: 99% Agreement: 99.57% 10 miuntes to get the result. MOQ for each: 500 tests, 25 tests/box,
SolGent DiaPlexQâ?¢ Novel Coronavirus (2019-nCoV) Detection Kit CE-IVD Real-Time OneStep RT-PCR based assay system for detection of 2019-nCoV CE-IVD DiaPlexQâ?¢ Novel Coronavirus(2019-nCoV) Detection Kit is CE-IVD reagent. It is screening kit to detect Novel Corona Virus as 2019-nCoV from isolated total RNA. Basic principal of this kit is Real-time PCR method, which is able to detect specific target gene into total RNA. One step RT-PCR contents are progressively apply for one tube RT(Reverse Transcription) reaction and PCR amplification. You can monitoring the nucleic acid amplification result based on real time condition through the amplification plot. The Control Template (2019-nCoV) is provide as positive control to assist the clinical sample data comparison analysis. - Detection target : 2019-nCoV ( COVID-19 ) - Target region : Orf1a, N gene - Detection technology : Real-Time OneStep RT-qPCR - Specimen type : Nasopharyngeal swab, Oropharyngeal swab, Sputum - Compatible instruments : CFX96â?¢ Real-Time PCR System (Bio-Rad), ABI 7500 / 7500 Fast Real-Time PCR System (Applied Biosystems) - PCR running time : ~ 120 mins - Simple & Rapid detection system: OneStep Multiplex RT-qPCR based detection - HotStart PCR: high-specificity - Reliable system: automatic PCR control (not Internal control) - Easy-to-use master mix: just adding template and Primer/Probe Mix - Positive control included (Plasmid)
SOFTEC COVID-19 Antigen Rapid Test (Nasal) The COVID-19 Antigen Rapid Test Cassette (Nasal Swab) is a lateral flow immunoassay designed for the qualitative detection of SARS-CoV 2 nucleocapsid antigens in nasal swabs from individuals with suspected COVID-19 by health care providers. Results are for SARS-CoV-2 nucleocapsid antigen identification. The COVID 19 Antigen Rapid Test Cassette (Nasal Swab) is intended for use by medical professionals or trained operators experienced in performing lateral flow tests. The price of the product is determined by the number of orders.
The COVID-19Antigen Rapid Test Cassette (Saliva) is a lateral flow immunoassay intended for the qualitative detection SARS-CoV-2 nucleocapsid antigens in saliva from individuals who are suspecte of COVID-19 by their healthcare provider. There are single pack and 25pcs products (SOFTEC COVID-19 Antigen Rapid Test (Saliva)25pcs Pack). The price of the product is determined by the number of orders.
1pc/box; 5pc/box; 20pc/box;
Rapid Accurate Innovative Comfortable Lollipop style Integral This SARS-CoV-2 Antigen Kit (Saliva Pen) is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid antigen in saliva specimens from individuals who are suspected of COVID-19. The most suitable for over-the-counter (OTC) home use by laymen in a non-laboratory setting. The most widely used testing scenarios, like for school kids test. The most integral design, simple and easy use lollipop style. The fastest result deliver: result is available within only 15 minutes. Cat.No Description Package size CG123201 Goldsite SARS-CoV-2 Antigen Kit(Saliva Pen) 1T CG123207 Goldsite SARS-CoV-2Antigen Kit(Saliva Pen) 7T CG123225 Goldsite SARS-CoV-2Antigen Kit(Saliva Pen) 25T
The COVID-19 Antigen Rapid Test Cassette is a lateral flow immunoassay intended for the qualitative detection SARS-CoV-2 nucleocapsid antigens in nasopharyngeal swab and oropharyngeal swab from individuals who are suspected of COVID-19 by their healthcare provider. Results are for the identification of SARS-CoV-2 nucleocapsid antigen
CLIA Waived Use of this test with all authorized specimen types is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform moderate or high complexity tests. This test is also authorized for use with fingerstick whole blood specimens only at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. The CLIA Waived COVID-19 IgG/IgM Rapid Test Device is an in vitro immunoassay for the direct and qualitative detection of anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG in human whole blood, serum, or plasma. The test is for professional use only. Indication: Qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood (sodium EDTA), serum, or plasma (sodium EDTA). Intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Emergency use of this test is limited to authorized laboratories. About Test Device EUA Authorized CE Mark Test does NOT give positive or negative result for COVID-19 virus. This is an antibody test, it only indicates past or recent infection. Read Results in 15 Minutes 9 Month Expiration from Date of Manufacture Contents 20 Test Devices 20 Disposable Pipettes 20 Alcohol Prep Pads Sterile Safety Lancets Buffer Package Insert
The CareStart COVID-19 Antigen Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals who are either suspected of COVID-19 by their healthcare provider within the first five days of symptom onset or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet the requirements to perform moderate, high, or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., inpatient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. Lateral flow assay Detect SARS-CoV-2 nucleocapsid protein antigen Rapid results within 10-15 minutes Intended at POC setting (i.e., in patient care settings) by medical professionals operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation For use under the Emergency Use Authorization (EUA) only For in vitro diagnostic use only For prescription use only For use with direct anterior nasal and nasopharyngeal swab specimens Clinical Performance 93.75% PPAa and 99.32% NPAb when used with nasopharyngeal swab 87.18% PPAa and 100% NPAb when used with anterior nasal swab
Master Carton - Contains 625 Tests For International Sale Only - Call for Pricing The COVID-19 IgG/IgM Rapid Test Device is an in vitro Immunoassay for the direct and qualitative detection of anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG in human whole blood, serum, or plasma. The test is for professional use only. Indication: Qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood (sodium EDTA), serum, or plasma (sodium EDTA). Intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. About Test Device Gives Positive or Negative Result for COVID-19 IgM/IgG antibodies Read Results in 15 Minutes Contents of each box 25 Test Devices 25 Disposable Pipettes 25 Alcohol Prep Pads Sterile Safety Lancets Buffer Package Insert
Big range of self Covid tests.
COVID-19 AG detection of SARS-CoV-2 antigen
Intended use: AIVD COVID-19(SARS-CoV-2) IgG/IgM Rapid Test is a single use, rapid device for qualitative detection of total antibodies against 2019 novel coronavirus (SARS-CoV-2) in human serum, plasma or whole blood specimens. The kit is intended for screening of patients suspected for infection with SARS-CoV-2, and as an aid in the diagnosis of the coronavirus disease 2019 (COVID-19). Descriptionï¼? Novel coronavirus pneumonia (NCP) or SARS-COV-2, that was officially named by the WHO as â??Corona virus disease 2019â?? (COVID-19), is a respiratory infection caused by a new virus that was first identified in late 2019. IgM/IgG Rapid Kit can specifically detect IgM and IgG antibodies of COVID-19, covering the entire course of infection and recovery period of patients. This approach improves the overall diagnosis of COVID-19 in both acute and recovery phases of illness. This kit utilizes the principle of colloidal gold immunochromatography to qualitatively detect the new coronavirus (COVID-19) IgG / IgM antibodies in human serum and plasma. Lateral flow immunochromatographic assay provides an easy workflow, short turnaround time, and rapid diagnosis of COVID-19 suspected patients. This method does not require expensive medical instruments and consumables. Just take the specimen and add it to the sample well, and then add the required amount of a diluent. The IgG / IgM antibodies in the sample will interact with the colloidal gold-labeled COVID-19 recombinant antigen on the conjugate pad. Then the conjugate pad will release re-solubilized conjugate onto the nitrocellulose membrane. The nitrocellulose membrane (NC membrane) diffuses it forward. As the sample moves along the device binding reagents situated on the nitrocellulose membrane bind to the target at the test line. If the sample contains a COVID-19 IgG antibodies, they will bind to the colloidal gold-labeled novel coronavirus recombinant antigen, diffuse forward, and then react with the anti-human IgG antibodies immobilized on the NC membrane detection line (T2 line). Similarly, if the specimen contains IgM antibodies to COVID-19, the antibodies will react with antigen-coated particles, the conjugate migrate laterally forward, and cause a colored line (T1 line). The darker the color of colloidal gold on the test line, the higher the concentration antibodies to COVID-19 in the sample. Accuracy:ï¼?> 90% Specificity: 97% Basic Protocolï¼? 1. Remove the test specimen, required reagents from storage conditions, and equilibrate to room temperature. 2. Unpack the aluminum foil bag, place the test horizontally on the table and number it. 3. Add 10ul serum, plasma or whole blood sample to the sample well with a pipette or a dropper. Slowly add 2 drops of sample dilution (about 60uL) to the sample well. 4. Read the results within 10-15 minutes after adding the sample, and the results will be invalid after 30 minutes.
AIVD Biotechs COVID-19 Ag test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein (NP) antigen from SARS-CoV-2 in direct nasal swabs from individuals suspected of COVID-19. Description This kit utilizes the principle of latex bead immunochromatography to qualitatively detect the new coronavirus (COVID-19) Np antigen in human nasal swabs. Lateral flow immunochromatographic assay provides an easy workflow, short turnaround time, and rapid diagnosis of COVID-19 suspected patients. The test contains latex bead conjugate pad and a membrane strip pre-coated with antibodies specific to SARS-CoV-2 antigen on the test lines (T). If SARS-CoV-2 antigen is present in the specimen, a visible band appears on the test lines (T) as antibody-antigen-antibody latex bead complex forms. The control line (C) is used for procedural control and should always appear if the test is performed correctly. This method does not require expensive medical instruments and consumables. Just take the specimen and add it to the sample well. If sample contains the antigen, it will interact with the latex bead-labeled COVID-19 anti-SARS-COV-2 NP antibodies on the conjugate pad. Required components 1. A foil pouch with a desiccant and a single-use test card, 1 piece 3. Sterile swab, 1 piece 3. Extraction buffer tube (1 ml), 1 tube. 4. Instructions for use, 1 piece. Specimen requirements: 1. Nasopharyngeal swab specimen. 2.Specimen should be tested as soon as possible upon collection. If the sample has to be stored, store the swab sample at room temperature for up to 1 hour or 2~8â?? for up to 4 hours prior to testing. Specimen preparation 1. Insert the extraction buffer tube into the tube rack, make sure that the sample tube is firmly upright and touches the bottom of the rack. 2. Insert the swab into an extraction buffer tube. 3. Gently stir the swab in the tube, and then left swab inside the tube for 1 minute or Mix on the vortex mixer for about 30 seconds, 4. The sample should be tested immediately after collection. If it cannot be tested in time, it should be stored in the virus transport matrix. The specimens can be stored at 2-8C for 4 hours Basic Protocol Step 1: If the sample is refrigerated, remove the sample to be tested and the required reagents from the storage conditions, equilibrate to room temperature (15~30C) Step 2: When preparing to test, open the aluminum foil bag, take out the test card, and lay it flat on a table. Step 3: Mark the sample number on the test card, Step 4: Using pipette add 50ul of the sample into a sample well on the device, Step 5: Read the result within 15 minutes, Please read the result after 15 minutes. After observing and recording the result, please discard the test card to avoid affecting the result judgment. Do not read test results after 30 minutes. It may give false results.
The NeoPlexTM COVID-19 Detection Kit Assay is a real-time RT-PCR in vitro diagnostic test intended for the qualitative detection of RNA from SARS-CoV-2 isolated and purified from respiratory specimens* obtained from individuals who meet COVID-19 clinical and/or epidemiological criteria. The NeoPlexTM COVID-19 Detection Kit is for use only under Emergency Use Authorization (EUA) in the US laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C.�§263a, to perform high complexity tests. CE & FDA Approved and MHRA Registered for UK
STANDARD M nCoV Real-Time Detection kit is used for rapid identification and detection of novel coronavirus (2019-nCoV) nucleic acids in human nasopharyngeal swabs and throat swab samples. - One tube reaction for identification and detection of 2019-nCoV - One-step Real-Time RT-PCR - Provide all reagents required for PCR - Designed according to WHO interim guidance for laboratory testing for 2019 novel coronavirus (2019-nCoV) in humans" - nCoV primers/probes ORF1ab (RdRp) gene, E gene - Provide Internal controls - Test time : 90mins - Specimen : Nasopharyngeal swab, Oropharyngeal swab, Sputum - Applicable machine : CFX96. ABI7500 - CE, FDA EUA
iONEBIO Novel-CoV19 Real-time RT-LAMP-PCR Detection Kit Our In-vitro Diagnostic product enables precise and efficient detection of the Coronavirus disease (2019-nCoV), utilizing Real-time RT LAMP PCR Real-time Reverse-Transcription Loop-mediated isothermal Amplification PCR method on nasopharyngeal swab specimen of a suspected patient. - Detection target : 2019-nCoV ( COVID-19 ) - Target region : N gene - Detection technology : Real-Time RT -LAMP PCR (with OneStep) - Specimen type : Nasopharyngeal swab, Oropharyngeal swab, etc - PCR running time : 20 mins - Compatible PCR Device : CFX96TM Real-Time PCR System (Bio-Rad) Key Characteristics Rapid Detection System : Implementation of isothermal reaction method enables for 20-min test time SYBR green Application : Fluorometric Detection enables for High Specificity One step qRT-PCR system : en-bloc analysis without separate reverse-transcription process User-Friendly Diagnostic System: Analysis possible only with the RNA specimen Inclusion of Positive Control (Plasmid form) iONEBIOs RT-LAMP PCR Kit is groundbreaking rapid and accurate; thus is the most competitive diagnostic kit for COVID-19 available in the global market.
Specimen Collection: Nasal, Saliva Packing: 1 test / 25 Tests Accurancy: >93% Specificy: 99% Warranty: 2 year Certificate: CE, ISO13485,BfArM,BASG,MDA,Thai FDA
1 test*500box/ctn saliva test easy to test COVID CE PEI EU list products factory OEM supply
